Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06377735
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-04-17
Brief Title:
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization BAI-BACE for Advanced Lung Squamous Cell Carcinoma a Multicenter Single-arm Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bronchial arterial infusion plus bronchial arterial chemoembolization BAI-BACE has been reported as non-first-line therapy to treat lung cancer in many hospitals in China BAI which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor Then BACE could seal off the tumor vessels In this study we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma
Detailed Description:
This study is a multicenter interventional study to explore the efficacy safety of BAI-BACE as non-first-line therapy for advanced central squamous cell carcinoma Lung cancer is the leading cause of cancer-related death worldwide Owing to the insidious symptom most patients about 75 are diagnosed at the advanced stage of the disease and thus cannot undergo resection The central squamous cell carcinoma accounts for 25 of all cases of lung cancer The first-line standard treatment for advanced central squamous cell carcinoma is combined chemoradiotherapy and chemoradiotherapy is usually as the second-line However treatment failure is noted in many patients and those patients often face the limited therapy choice and poor prognosis Bronchial arterial infusion plus bronchial arterial chemoembolization BAI-BACE has been reported to treat lung cancer in many hospitals in China BAI which use chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor Then BACE could seal off the tumor vessels The systemic toxicity of this surgery is low and tolerable This study will provide clinical evidence that BACE-BAI will provide survival benefit for patients with advanced central squamous cell carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None